Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132035 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
A Phase 1 study of Age-related Wet Macular Degeneration, sponsored by Caregen Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT06132035 is a Phase 1 study of Age-related Wet Macular Degeneration that is actively recruiting participants, run by Caregen Co.. The registered enrollment target is 45 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT06132035, a Phase 1 study of Age-related Wet Macular Degeneration, is actively recruiting participants, sponsored by Caregen Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CG-P5 peptide
- DRUG Aflibercept Injection [Eylea]
Study Locations (7)
Pennsylvania
- CBCC Global Research Site:002 - Erie
- CBCC Global Research Site:007 - Philadelphia
Connecticut
- CBCC Global Research Site:005 - Manchester
Florida
- CBCC Global Research Site:006 - Deerfield Beach
Georgia
- CBCC Global Research Site:001 - Augusta
Indiana
- CBCC Global Research Site:004 - Carmel
North Dakota
- CBCC Global Research Site:003 - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-22 |
| Est. Completion | 2025-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06132035
The ClinicalTrials.gov registry entry for NCT06132035 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caregen Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Wet Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06132035 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Pennsylvania, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT06132035 about?
NCT06132035 is a clinical study titled "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration". This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
What is the current status of trial NCT06132035?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-12-22. Estimated completion is 2025-08.
What conditions does trial NCT06132035 study?
This clinical trial studies the following conditions: Age-related Wet Macular Degeneration.
What interventions are being tested in trial NCT06132035?
The interventions under investigation include: Placebo (DRUG), CG-P5 peptide (DRUG), Aflibercept Injection [Eylea] (DRUG).
Who is sponsoring clinical trial NCT06132035?
This trial is sponsored by Caregen Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132035 being conducted?
This trial has 7 study locations across Connecticut, Florida, Georgia, Indiana, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.